Do NSAIDs affect the progression of osteoarthritis?

被引:85
作者
Ding, CH [1 ]
机构
[1] Univ Tasmania, Ctr Populat Hlth Res, Hobart, Tas 7000, Australia
[2] Anhui Med Univ, Hefei, Peoples R China
关键词
NSAIDs; osteoarthritis; progression; cartilage;
D O I
10.1023/A:1015504632021
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
NSAIDs are widely used to alleviate the symptoms of OA. It remains controversial as to what effects these agents have on the progression of OA. In vitro studies showed several types of NSAIDs (e.g., sodium salicylate, indomethacin) inhibited the synthesis of cartilage matrix component, but some types of NSAIDs (e.g., aceclofenac, meloxicam, nimesulide) increased the matrix component synthesis and protected the chondrocytes against apoptosis, while others (e.g., piroxicam) had no effects. Studies in animal models verified that NSAIDs had favourable or detrimental action on OA progression, even the same NSAID (e.g., naproxen, tiaprofenic acid) had reverse effects on articular cartilage in different studies. Preliminary clinical trials revealed some NSAIDs such as indomethacin had a negative influence on joint structure, other NSAIDs such as diclofenac and naproxen had no acceleration of radiographic damage to OA within 2-years of treatment. So far, there are no convincing data to show the widely used NSAIDs and recommended selective COX-2 inhibitor have favourable effects on cartilage. Therefore, it is necessary and valuable to clarify the effects of these NSAIDs on cartilage in patients with OA using validated non-invasive methods such as MRI.
引用
收藏
页码:139 / 142
页数:4
相关论文
共 27 条
  • [1] Effects of diclofenac, aceclofenac and meloxicam on the metabolism of proteoglycans and hyaluronan in osteoarthritic human cartilage
    Blot, L
    Marcelis, A
    Devogelaer, JP
    Manicourt, DH
    [J]. BRITISH JOURNAL OF PHARMACOLOGY, 2000, 131 (07) : 1413 - 1421
  • [2] Chan CC, 1999, J PHARMACOL EXP THER, V290, P551
  • [3] DIEPPE P, 1993, BRIT J RHEUMATOL, V32, P595
  • [4] DINGLE JT, 1996, EUR J RHEUMATOL INFL, V16, P47
  • [5] Felson DT, 1998, ARTHRITIS RHEUM, V41, P1343, DOI 10.1002/1529-0131(199808)41:8<1343::AID-ART3>3.0.CO
  • [6] 2-9
  • [7] Effects of tenidap on the progression of osteoarthritic lesions in a canine experimental model - Suppression of metalloprotease and interleukin-1 activity
    Fernandes, JC
    Caron, JP
    MartelPelletier, J
    Jovanovic, D
    Mineau, F
    Tardif, G
    Otterness, IG
    Pelletier, JP
    [J]. ARTHRITIS AND RHEUMATISM, 1997, 40 (02): : 284 - 294
  • [8] Gencosmanoglu BE, 2001, RES EXP MED, V200, P215
  • [9] Goldring MB, 2000, ARTHRITIS RHEUM-US, V43, P1916, DOI 10.1002/1529-0131(200009)43:9<1916::AID-ANR2>3.0.CO
  • [10] 2-I